Comments
Suven Life Sciences announced positive topline results from its Phase 2a proof-of-concept study for Ropanicant (SUVN-911), a novel treatment for moderate to severe major depressive disorder (MDD). The open-label study, involving 41 patients across 10 US sites, demonstrated statistically significant improvements in depressive symptoms as measured by the Montgomery-Asberg Depression Rating Scale (MADRS).
The shares of Suven Life Sciences Limited were trading flat at ₹158.01 on the NSE at 12.45 pm.
Patients treated with Ropanicant showed mean MADRS score improvements of 5.9-13.4 points on day 7, and 10.4-12.7 points on day 14 across different doses. The drug was generally well tolerated, with no serious adverse events reported.
Suven plans to advance Ropanicant to a double-blind, placebo-controlled Phase 2b study in early 2025. The company will present the topline data at the Neuroscience-2024 conference in Chicago this October.
Ropanicant is being developed to address the limitations of existing MDD treatments, potentially offering rapid onset of action without sexual dysfunction side effects.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.